Loading patent…
AssigneeNorthwestern University
InventorsNoel P. Bouck, David W. Dawson, Paul R. Gillis, Olga Volpert, Susan E. Crawford, Veronica M. Stellmach
Estimating the term…
The present invention provides a method of inhibiting angiogenesis within a tissue by providing exogenous PEDF to cells associated with the tissue. The presence of exogenous PEDF inhibits angiogenesis within the tissue, in part by interfering with the ability of vascular endothelia to expand within the tissue. The invention also provides a method for determining the severity of a tumor by assaying for the presence of PEDF within the tumor. The invention further provides a method of inhibiting endothelial cell migration, a method of stimulating the growth of hair in a mammal, a method for inhibiting the growth of a tumor, a method of inducing differentiation of a neuroblastoma cell, a method of slowing the growth of a neuroblastoma cell, and method of treating ischemic retinopathy in a mammal. To facilitate the inventive methods, the present invention provides pharmaceutical compositions including sources of PEDF.
A method of inhibiting angiogenesis within a tissue, said method comprising providing exogenous PEDF to endothelial cells associated with said tissue under conditions sufficient for said PEDF to inhibit angiogenesis within said tissue.
A method of inhibiting endothelial cell migration, said method comprising providing exogenous PEDF to said cells under conditions sufficient for said PEDF to inhibit endothelial cell migration.
A method of stimulating the growth of hair in a mammal, said method comprising providing exogenous PEDF to cells associated with the skin of said mammal under conditions sufficient for said PEDF to stimulate the growth of hair in said mammal.
A method for inhibiting the growth of a tumor, said method comprising providing exogenous PEDF to endothelial cells associated with said tumor under conditions sufficient for said PEDF to inhibit the migration of said endothelial cells within and to said tumor such that the growth of said tumor is inhibited.
A pharmacological composition comprising a source of PEDF and a suitable diluent.
A method of determining the severity of a tumor by assaying for the presence of PEDF within the tumor, wherein the absence of PEDF within the tumor indicates an advanced state and the presence of PEDF within the tumor indicates an early state of said tumor.
A method of inducing differentiation of a neuroblastoma cell, said method comprising administering PEDF to said cell, thereby inducing differentiation of said cell.
A method of slowing the growth of a neuroblastoma cell, said method comprising administering PEDF to said cell, thereby slowing the growth of said cell.
A method of treating ischemic retinopathy in a mammal, said method comprising providing exogenous PEDF to endothelial cells associated with the eye of said mammal under conditions sufficient for said PEDF to inhibit angiogenesis in said eye, thereby treating said ischemic retinopathy.
A method of inhibiting angiogenesis within a tissue in a mammal, said method comprising providing exogenous PEDF systemically to said mammal, under conditions sufficient for said PEDF to inhibit angiogenesis within said tissue.
A method of upregulating the expression of PEDF in a cell in a tissue, said method comprising inducing hyperoxia in said tissue, thereby upregulating the expression of PEDF in said cell.
A method of treating macular degeneration in a mammal, said method comprising providing exogenous PEDF to endothelial cells associated with the eye of said mammal under conditions sufficient for said PEDF to inhibit angiogenesis in said eye, thereby treating said macular degeneration.
A method of treating a benign neoplasia in a mammal, said method comprising administering PEDF to said mammal, thereby treating said benign neoplasia.
A method of inhibiting angiogenesis within a tissue, said method comprising providing exogenous PEDF to endothelial cells associated with said tissue in conjunction with at least one other treatment selected from the group consisting of radiation, chemotherapy, the use of at least one biological response modifier, and laser treatment, under conditions sufficient for said PEDF to inhibit angiogenesis within said tissue.
Dependencies are inferred from the claim text.